Taro Masunari

Dr. Taro Masunari

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TJTatsuro Jo
Tatsuro Jo
YSYoshio Saburi
Yoshio Saburi
TMTaro Masunari
Taro Masunari
KNKazuhiro Noguchi
Kazuhiro Noguchi
TSTakahiro Sakai
Takahiro Sakai
TKToru Kiguchi
Toru Kiguchi
We prospectively evaluated whether cytotoxic T-lymphocyte (CTL) activation and T-cell receptor (TCR) Vβ clonality predict treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) cessation in chronic-phase chronic myeloid leukemia (CML). Forty-five patients with sustained deep molecular response (DMR) were enrolled (On-TKI, n = 38; Off-TKI, n = 7) and underwent one-year immuno-monitoring from consent. The primary endpoint was 12-month TFR, defined as retention of MR4. Overall, 32/45 patients (71%) maintained TFR at 12 months. Longer TKI exposure and stable DMR were associated with TFR; notably, patients fulfilling “≥7 years of TKI plus ≥1 year of DMR” and exhibiting CTL activation features—CD8 > CD4, memory > effector, and/or highly activated CTL clones on TCR Vβ repertoire—showed the highest likelihood of durable TFR. By contrast, NK cells, effector Tregs, and G-/M-MDSCs did not discriminate TFR status in this cohort. Although antigen specificity against CML stem cells was not directly tested, the memory-dominant CTL phenotype is consistent with immune control after antigen reduction. These findings suggest that a simple, clinically accessible strategy based on flow cytometric CTL profiling and TCR Vβ clonality may help inform TKI discontinuation decisions in CML. External validation is warranted to confirm transportability and refine clinical thresholds.

2 August 2025 in American Journal of Hematology
Verified
Journal Article
Open access
MSMasuho Saburi
Masuho Saburi
TMTaro Masunari
Taro Masunari
NFNoriko Fukuhara
Noriko Fukuhara
YIYuichiro Inagaki
Yuichiro Inagaki
ASArika Shimura
Arika Shimura
NSNaohiro Sekiguchi
Naohiro Sekiguchi

5 August 2025 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
KHKenta Hayashino
Kenta Hayashino
NFNobuharu Fujii
Nobuharu Fujii
SMSatsuki Murakami
Satsuki Murakami
TMTaro Masunari
Taro Masunari
IYIsao Yoshida
Isao Yoshida
YMYoshinobu Maeda
Yoshinobu Maeda